Clinical efficacy observation of moxifloxacin in the treatment of community-acquired pneumonia
莫西沙星治疗社区获得性肺炎的临床疗效观察

摘要

目的 研究莫西沙星治疗社区获得性肺炎的临床疗效观察。方法 抽取我院于2023年2月-2024年2月收治的58例社区获得性肺炎患者，按照所有患者进行分配，将其分为普通组（29例）与指导组（29例）。最后对其患者治疗效果情况、不良并发症情况进行统计分析。结果 经分析，指导组患者并发症发生情况为（20.83%）明显低于普通组患者为（54.16%），故有对比意义（P＜0.05）。指导组患者治疗效果情况有显著改善，数据对比在统计学上具有明显差异（P＜0.05）。结论 莫西沙星在治疗社区获得性肺炎方面具有使用简便、无需进行皮肤测试、一次性给药以及相对较高安全性等多项优势。因此，国内外权威的治疗指南都强烈推荐使用莫西沙星作为治疗所有社区获得性肺炎的首选药物。

Abstract

Objective: To investigate the clinical efficacy of moxifloxacin in the treatment of community-acquired pneumonia. Method: A total of 58 patients with community-acquired pneumonia admitted to our hospital from February 2023 to February 2024 were selected and allocated into a control group (29 cases) and a guidance group (29 cases) according to the distribution of all patients. Finally, statistical analysis was conducted on the treatment effectiveness and adverse complications of the patients. Result: After analysis, the incidence of complications in the guidance group (20.83%) was significantly lower than that in the control group (54.16%), indicating a comparative significance (P<0.05). The treatment effect of the guidance group patients has significantly improved, and the data comparison shows significant statistical differences (P<0.05).
Conclusion  : Moxifloxacin has multiple advantages in the treatment of community-acquired pneumonia, including ease of use, no need for skin testing, one-time administration, and relatively high safety. Therefore, authoritative treatment guidelines both domestically and internationally strongly recommend the use of moxifloxacin as the preferred medication for the treatment of all community-acquired pneumonia.